Investigation of medicinal plants from Madagascar against DPP-IV linked to type 2 diabetes

Beidokhti, Maliheh Najari; Lobbens, Eva S.B.; Rasoavaivo, P; Jäger, Anna K.

doi:10.1016/j.sajb.2018.01.018

Cited by 17 publications

(11 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several recent progresses of DPP-IV inhibitors have shown that chemical components of natural sources were found with potent DPP-IV inhibitory activity (Kim et al 2018). A study has shown that Berberine which is an alkaloid have potency to inhibit the DPP-IV enzyme, but activity was lower compared to sitagliptin (Beidokhti et al 2018). which was in accordance with DPP-IV inhibiting activity of palmatine observed in our study.…”

Section: Discussionsupporting

confidence: 91%

In-vitro anti-diabetic activity and in-silico studies of binding energies of palmatine with alpha-amylase, alpha-glucosidase and DPP-IV enzymes

Okechukwu¹,

Sharma²,

Tan³

et al. 2020

PHAR

View full text Add to dashboard Cite

Palmatine a protoberberine alkaloid has been previously reported to possess in vivo antidiabetic and antioxidant property. The aim of the experiment is to evaluate the in vitro antidiabetic activity and in-silico studies of the binding energies of Palmatine, acarbose, and Sitagliptin with the three enzymes of alpha-amylase, alpha-glucosidase, and dipeptidyl peptidase-IV (DPP-IV). The in vitro antidiabetic study was done by evaluating the inhibitory effect of palmatine on the activities of alpha-amylase, alpha-glucosidase, and DPP-IV. Acarbose, and sitagliptin was used as standard drug. The molecular docking study was performed to study the binding interactions of palmatine with alpha-glucosidase, a-amylase, and DPP-IV. The binding interactions were compared with the standard compounds Sitagliptin and acarbose. Palmatine with IC50 (1.31 ± 0.27 µM) showed significant difference of (< 0.0001) higher inhibiting effect on alpha-amylase and weak inhibiting effect on alpha-glucosidase enzyme with IC50 (9.39 ± 0.27 µM) and DPP-IV with IC50 (8.7 ± 1.82 µM). Palmatine possess inhibition effect on the three enzymes.

show abstract

Section: Discussionsupporting

confidence: 91%

In-vitro anti-diabetic activity and in-silico studies of binding energies of palmatine with alpha-amylase, alpha-glucosidase and DPP-IV enzymes

Okechukwu¹,

Sharma²,

Tan³

et al. 2020

PHAR

View full text Add to dashboard Cite

show abstract

“…A dipeptidyl peptidase IV (DPP-IV) inhibitors increase the activation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), leading to the inhibition of secretion of glucagon and enhancement of β-cells functionality [ 98 ]. Thus the control of DPP-IV activity is an essential factor in management of type 2 diabetes, and amentoflavone (6), with an IC 50 value of 3.9 ± 0.5 μM, was recognized as a potential DPP-IV inhibitor [ 99 ].…”

Section: Bioactive Secondary Metabolites From Juniperus mentioning

confidence: 99%

The Current Status of the Pharmaceutical Potential of Juniperus L. Metabolites

Tavares

Seca

2018

Medicines

View full text Add to dashboard Cite

Background: Plants and their derived natural compounds possess various biological and therapeutic properties, which turns them into an increasing topic of interest and research. Juniperus genus is diverse in species, with several traditional medicines reported, and rich in natural compounds with potential for development of new drugs. Methods: The research for this review were based in the Scopus and Web of Science databases using terms combining Juniperus, secondary metabolites names, and biological activities. This is not an exhaustive review of Juniperus compounds with biological activities, but rather a critical selection taking into account the following criteria: (i) studies involving the most recent methodologies for quantitative evaluation of biological activities; and (ii) the compounds with the highest number of studies published in the last four years. Results: From Juniperus species, several diterpenes, flavonoids, and one lignan were emphasized taking into account their level of activity against several targets. Antitumor activity is by far the most studied, being followed by antibacterial and antiviral activities. Deoxypodophyllotoxin and one dehydroabietic acid derivative appears to be the most promising lead compounds. Conclusions: This review demonstrates the Juniperus species value as a source of secondary metabolites with relevant pharmaceutical potential.

show abstract

“…Also, the activity of amentoflavone was evaluated in terms of dipeptidyl peptidase‐4 (DPP‐4) enzyme inhibition, which has an important role in the control of type 2 diabetes. Beidokhti, Lobbens, Rasoavaivo, Staerk, and Jäger (2018) showed that amentoflavone (IC 50 3.9 ± 0.5 µM) is a potent DDP‐4 enzyme inhibitor. To date, no activity studies of amentoflavone on pancreatic lipase have been found.…”

Section: Resultsmentioning

confidence: 99%

Activity‐guided isolation of α‐amylase, α‐glucosidase, and pancreatic lipase inhibitory compounds from Rhus coriaria L

Gök

Orhan

Gürbüz

et al. 2020

Journal of Food Science

View full text Add to dashboard Cite

The leaves and fruits of Rhus coriaria are traditionally used in Turkey for the treatment of diabetes. The aim of the present study is to determine α-amylase, α-glucosidase, and pancreatic lipase inhibitory activities of R. coriaria leaf and fruit ethanol extracts (80%), and to isolate active compounds against these enzymes. As a result of the activity-guided isolation, the active compounds were determined as the amentoflavone, agathisflavone, and 1,2,3,4,6-penta-O-galloyl-βglucopyranose. Agathisflavone, amentoflavone, and penta-O-galloyl-β-glucopyranose inhibited α-glucosidase with 11.4 ± 0.9, 11.3 ± 0.7, and 4.1 ± 0.1 μM IC 50 values, respectively. Furthermore, penta-O-galloyl-β-glucopyranose inhibited αamylase with 6.32 ± 0.18 μM IC 50. These three compounds also significantly inhibited (P < 0.05) pancreatic lipase. The results of high-performance liquid chromatography analysis showed that penta-O-galloyl-β-D-glycopyranose was one of the main compounds in both fruit and leaf extracts. Therefore, it may be considered that R. coriaria fruit and leaf extracts can be standardized on this substance and used in the development of both medicinal products and functional food for diabetes.

show abstract

Investigation of medicinal plants from Madagascar against DPP-IV linked to type 2 diabetes

Cited by 17 publications

References 47 publications

In-vitro anti-diabetic activity and in-silico studies of binding energies of palmatine with alpha-amylase, alpha-glucosidase and DPP-IV enzymes

In-vitro anti-diabetic activity and in-silico studies of binding energies of palmatine with alpha-amylase, alpha-glucosidase and DPP-IV enzymes

The Current Status of the Pharmaceutical Potential of Juniperus L. Metabolites

Activity‐guided isolation of α‐amylase, α‐glucosidase, and pancreatic lipase inhibitory compounds from Rhus coriaria L

Contact Info

Product

Resources

About